|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.35 USD | +11.97% |
|
+19.79% | +84.30% |
| 07/05 | Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial | RE |
| 06/05 | Novavax beats first-quarter revenue estimates on strength in vaccine deals | RE |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bullish | Bullish |
| Resistance | 55.6 | 57.8 | 73.94 |
| Spread/Res. | -2.25% | -5.97% | -26.49% |
| Spread/Supp. | +19.79% | +51.43% | +52.63% |
| Support | 45.37 | 35.89 | 35.61 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- MRNA Stock
- Charts Moderna, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition